您的位置:首页 > 会议日程
Philippe Moreau
分享到:
CHU de Nantes
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM). 
He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator or co-PI of many international randomized phase 3 clinical trials: Tourmaline (Ixazomib for relapsed myeloma), Aspire (Carfilzomib for relapsed myeloma), Endeavor (Carfilzomib for relapsed myeloma), Stratus (Pomalidomide for relapsed myeloma), Pollux (Daratumumab for relapsed myeloma), Arrow (weekly versus biweekly Carfilzomib for relapsed myeloma) or Cassiopeia (Daratumumab for frontline therapy in transplant eligible patients). 
His research is widely published. Professor Moreau has authored or coauthored more than 300 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. He is a member of the editorial boards of Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.

讲座视频:0

论文摘要:1

1100

0

0

日期 时间 会场 Session 角色 讲题
2020-09-26 09:30-10:00 主会场/大宴会厅

大会报告 17

讲者 Management of Multiple Myeloma in the Era of Novel Agents